nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2023, 01, v.42;No.423 62-66
李达辨治原发性骨髓纤维化经验
基金项目(Foundation): 广东省名老中医药专家传承工作室基金项目(批文号:粤中医办函[2017]209号)
邮箱(Email):
DOI: 10.16295/j.cnki.0257-358x.2023.01.012
移动端阅读
摘要:

原发性骨髓纤维化(PMF)是一种恶性骨髓增殖性疾病,西医目前尚无特效疗法,中医药在改善症状、缓解病情、增效减毒方面独具优势。李达教授衷中参西,病证结合、多维辨析,认为瘀毒内蕴、脾肾两虚、正衰毒亢是PMF的基本病机,故临证以扶正祛邪为治则,提出健脾补肾、活血解毒、和解增效等治法,将内服与外敷有机结合,有效地改善了PMF患者贫血、巨脾及骨髓纤维化表现。附验案1则。

Abstract:

Primary myelofibrosis(PMF) is a malignant myeloproliferative disease. Western medicine has no specific treatment for it at present,but traditional Chinese medicine has unique advantages in relieving symptoms,alleviating the condition,enhancing the effect and reducing the toxicity. Professor LI Da combines diseases and syndromes with multidimensional analysis based on modern and traditional medicine theroies.He believes that the basic pathogenesis of PMF are the deficiency of spleen and kidney,blood stasis and toxin stagnation,deficiency of healthy qi and predominance of pathogenic factors. He proposes that invigorating spleen and tonifying kidney,promoting blood circulation and resolving toxin,reconciling and enhancing efficiency,and the combination of internal administration and external external application under the principle of strengthening healthy qi to eliminate pathogenic factors can effectively relieve the symptoms of anemia,giant spleen and myelofibrosis in PMF patients. One tested case is attached.

参考文献

[1] VERSTOVSEK S,KANTARJIAN H,MESA R A,et al.Safety and efficacy of INCB018424,a JAK1 and JAK2inhibitor,in myelofibrosis[J]. N Engl J Med,2010,363(12):1117-1127.

[2]中华医学会血液学分会白血病淋巴瘤学组.原发性骨髓纤维化诊断与治疗中国指南(2019年版)[J].中华血液学杂志,2019,40(1):1-7.

[3]李信阳,杨威.原发性骨髓纤维化诊治进展[J].中国实用内科杂志,2018,38(2):107-112.

[4]陈羡男,陈瑶,李达.浅析和血法的形成及其血液病辨治[J].中华中医药杂志,2018,33(6):2517-2519.

[5]赵佶.圣济总录[M].郑金生,校注.北京:人民卫生出版社,2013:1077.

[6]丁光迪.诸病源候论校注[M].北京:人民卫生出版社,2013:376.

[7]刘博雅,陈曦,王京华.骨髓纤维化的发病机制及临床表现[J].现代肿瘤医学,2016,24(6):998-1001.

[8] GUGLIELMELLI P,VANNUCCHI A M. Struggling with myelofibrosis-associated Anemia[J]. Leuk Res, 2013,37(11):1429-1431.

[9]李明,王椿.骨髓纤维化贫血的研究进展[J].疑难病杂志,2017,16(3):321-324.

[10]韩雪娇,郭娜,朱美宣,等.红景天苷药理作用及其作用机理研究进展[J].中国生化药物杂志,2015,35(1):171-175.

[11]王颖,郭兰萍,黄璐琦,等.姜黄、莪术、郁金的化学成分与药理作用研究进展[J].中国药房,2013,24(35):3338-3341.

[12]卫强,孙涛.红豆杉的抗肿瘤活性成分及其衍生物研究进展[J].天然产物研究与开发,2016,28(10):1664-1675,1685.

[13]李文泉,范春琦,权红,等.方和谦学术思想研究[J].中医杂志,2010,51(6):491-494.

[14]李慧,李达.秉承李达和血法经验探索中医药介入血液肿瘤围化疗期治疗思路[J].中华中医药杂志,2019,34(7):3115-3118.

[15]李达,代喜平,胡永珍,等.青黛四黄散治疗慢性骨髓纤维化性巨脾症临床观察[J].辽宁中医杂志,2006,33(9):1144-1145.

[16]华海清.青黛的古今应用[J].中国中药杂志,1992,17(2):117-120.

[17]宋丹,张黎芳,蒋元品,等.古医籍四黄散方药记载及现代临床应用概况[J].国医论坛,2016,31(2):52-53.

基本信息:

DOI:10.16295/j.cnki.0257-358x.2023.01.012

中图分类号:R259;R249

引用信息:

[1]苏浩杰,戴晓峰,吴建伟,等.李达辨治原发性骨髓纤维化经验[J],2023,42(01):62-66.DOI:10.16295/j.cnki.0257-358x.2023.01.012.

基金信息:

广东省名老中医药专家传承工作室基金项目(批文号:粤中医办函[2017]209号)

检 索 高级检索